Advanced prostate cancer is cancer that has spread beyond the prostate to distant parts of the body. It is also called ...

Dalpiciclib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Hormone-Sensitive Prostate Cancer.

Abiraterone is under clinical development by Austhera BioSciences and currently in Phase II for Hormone-Sensitive Prostate Cancer.

Sep. 4, 2024 — A treatment paradox has recently come to light in prostate cancer: blocking testosterone production halts tumor growth in early disease, while elevating the hormone can delay ...

Abstract: Accurately predicting the impact of hormonal therapy on Prostate Cancer (PC) lesions is paramount for effective treatment planning and monitoring. This study proposes a comprehensive ...

4, 2024 — A treatment paradox has recently come to light in prostate cancer: blocking testosterone production halts tumor growth in early disease, while elevating the hormone can delay disease ...

This therapy is also called androgen deprivation therapy (ADT). Testosterone, an important male sex hormone, is the main fuel for prostate cancer cells, so reducing its levels may slow the growth of ...

Early and aggressive treatment strategies are crucial for improving outcomes in high-risk metastatic castration-sensitive prostate cancer. Combining androgen deprivation therapy with novel hormonal ...

Source Reference: Gudenkauf LM, et al "Balancing hormone therapy: Mitigating adverse effects of androgen-deprivation therapy and exploring alternatives in prostate cancer management" Am Soc Clin ...